Compare Bristol-Myers Squibb Co (BMY) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs D Wave Quantum Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.44 (market cap $116.30B), while D Wave Quantum Inc trades at $18.24 (market cap $7.02B). The key difference: Bristol-Myers Squibb Co is far larger — about 16.6× D Wave Quantum Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| BMY | QBTS | |
|---|---|---|
Market Cap | $116.30B | $7.02B |
Sector | Health | Technology |
52-Week High | $62.37 | $44.78 |
52-Week Low | $42.60 | $12.98 |
Enterprise Value | $152.24B | $6.48B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QBTS trades at $18.67, down 7.05% today amid a broader quantum computing sector sell-off. The stock exhibits a bearish technical signal despite oversold RSI readings, while fundamentals reveal severe losses with a net income margin of -2,957.23% and negative cash flow from operations. Recent news highlights its Nasdaq listing transfer and IDC MarketScape recognition as a quantum computing leader.
Analyst consensus remains strongly bullish with a $39.86 price target, but the stock faces significant execution risks, cash burn, and intense competition. Investment appeal hinges on speculative growth in commercial quantum adoption, yet profitability remains distant, demanding high risk tolerance from investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
